Aideen O'Neill
MBBS MRCP FRCPath
Post-Doctoral Researcher
I am a clinical haematologist and post-doctoral researcher in the haematopoietic transplantation and immunotherapy group of Prof. Ronjon Chakraverty. I recently completed my DPhil, funded by an MRC Clinical Research Training Fellowship (first supervisor: Prof. Chakraverty; second supervisor: Prof. Cristina Lo Celso (Imperial College/ Francis Crick Institute). Through my DPhil, I investigated the potential role of the bone marrow stroma in supporting T cells.
Prior to this, I completed my undergraduate degree in medicine at University College London. After qualifying I was awarded an NIHR Academic Foundation Post at UCL and an Academic Clinical Fellowship, also at UCL. I am a fellow of the Royal College of Pathologists.
I am interested in the potential to target bone marrow stromal changes as a route to improving adoptively-transferred T cell and molecular anti-leukaemia therapies.
Recent publications
Enhancement of mTORC1 Activity in Engineered Therapeutic CD4+T Cells Amplifies Tumour Infiltration but Impairs Cytotoxicity
Journal article
Sillito FE. et al, (2024), BLOOD, 144, 7196 - 7196
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing.
Journal article
Arulogun SO. et al, (2023), Am J Hematol, 98, 750 - 759
Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia.
Journal article
Arulogun SO. et al, (2022), Leuk Lymphoma, 63, 1496 - 1499
Graft Versus Leukemia: Current Status and Future Perspectives.
Journal article
O'Neill AT. and Chakraverty R., (2021), J Clin Oncol, 39, 361 - 372
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Journal article
McMillan A. et al, (2021), Br J Haematol, 192, e84 - e87
